[
  {
    "ts": "2025-12-01T04:15:00+00:00",
    "headline": "Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?",
    "summary": "The comeback may have begun.",
    "url": "https://www.fool.com/investing/2025/11/30/should-you-buy-this-biotech-stock-that-just-gained/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "1c880a23-bd39-395b-8bd1-0ee1634679b8",
      "content": {
        "id": "1c880a23-bd39-395b-8bd1-0ee1634679b8",
        "contentType": "STORY",
        "title": "Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?",
        "description": "",
        "summary": "The comeback may have begun.",
        "pubDate": "2025-12-01T04:15:00Z",
        "displayTime": "2025-12-01T04:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/ab58dd43aae10d16be26c1731460bf20",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Doctor talking to patient.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HG35Gvoxp.JAJKy3XMvuBw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/ab58dd43aae10d16be26c1731460bf20.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mmPDnm1ZSzbG22iJ2iOCNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/ab58dd43aae10d16be26c1731460bf20.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/30/should-you-buy-this-biotech-stock-that-just-gained/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-biotech-stock-just-gained-041500254.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-01T12:00:00+00:00",
    "headline": "Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)",
    "summary": "TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of a cash upfront and equity investment from Regeneron; companies to share worldwide development costs and future profits 50:50Collaboration combines Regeneron’s long-standing expertise in genetics, genetic medicines and clinical development with Tessera’s pioneering Gene WritingTM and",
    "url": "https://finance.yahoo.com/news/regeneron-tessera-therapeutics-jointly-develop-120000169.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "2fbf24fb-6404-376b-a9b2-56e3fd649a9d",
      "content": {
        "id": "2fbf24fb-6404-376b-a9b2-56e3fd649a9d",
        "contentType": "STORY",
        "title": "Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)",
        "description": "",
        "summary": "TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of a cash upfront and equity investment from Regeneron; companies to share worldwide development costs and future profits 50:50Collaboration combines Regeneron’s long-standing expertise in genetics, genetic medicines and clinical development with Tessera’s pioneering Gene WritingTM and",
        "pubDate": "2025-12-01T12:00:00Z",
        "displayTime": "2025-12-01T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
          "originalWidth": 800,
          "originalHeight": 126,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ohIVokMiKClSVTQVwyB2lw--~B/aD0xMjY7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 800,
              "height": 126,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YuYzNeQcIK6rRYN1HdT6UA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-tessera-therapeutics-jointly-develop-120000169.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-tessera-therapeutics-jointly-develop-120000169.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-01T16:10:00+00:00",
    "headline": "European Association for the Study of Diabetes (EASD) Annual Meeting Highlights 2025: Advancements in GLP-1RAs for Diabetes, Cardiovascular Treatments, and Therapies for Resistant Hypertension",
    "summary": "Key market opportunities include. Companies like Novo Nordisk, Regeneron, AstraZeneca, and Vertex are leading innovation, presenting new avenues for treatment in metabolic and cardiovascular conditions.Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The \"European Association for the Study of Diabetes (EASD): Annual Meeting 2025 Highlights\" report has been added to ResearchAndMarkets.com's offering.The European Association for the Study of Diabetes (EASD) is a leading academic, non-profit organization",
    "url": "https://finance.yahoo.com/news/european-association-study-diabetes-easd-161000354.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "a9f74a6d-e9e3-3d7e-99ce-0cebdf4a3342",
      "content": {
        "id": "a9f74a6d-e9e3-3d7e-99ce-0cebdf4a3342",
        "contentType": "STORY",
        "title": "European Association for the Study of Diabetes (EASD) Annual Meeting Highlights 2025: Advancements in GLP-1RAs for Diabetes, Cardiovascular Treatments, and Therapies for Resistant Hypertension",
        "description": "",
        "summary": "Key market opportunities include. Companies like Novo Nordisk, Regeneron, AstraZeneca, and Vertex are leading innovation, presenting new avenues for treatment in metabolic and cardiovascular conditions.Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The \"European Association for the Study of Diabetes (EASD): Annual Meeting 2025 Highlights\" report has been added to ResearchAndMarkets.com's offering.The European Association for the Study of Diabetes (EASD) is a leading academic, non-profit organization",
        "pubDate": "2025-12-01T16:10:00Z",
        "displayTime": "2025-12-01T16:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/european-association-study-diabetes-easd-161000354.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/european-association-study-diabetes-easd-161000354.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-01T14:48:00+00:00",
    "headline": "REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?",
    "summary": "Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.",
    "url": "https://finance.yahoo.com/news/regn-gains-21-5-month-144800616.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "cfe05573-b147-3012-8567-535ba98a4c7c",
      "content": {
        "id": "cfe05573-b147-3012-8567-535ba98a4c7c",
        "contentType": "STORY",
        "title": "REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?",
        "description": "",
        "summary": "Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.",
        "pubDate": "2025-12-01T14:48:00Z",
        "displayTime": "2025-12-01T14:48:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d7sHwZPFV1U3B4BGoNlXfg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k5CBlnqEqKxZI1S0BuG_ug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regn-gains-21-5-month-144800616.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regn-gains-21-5-month-144800616.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "BAYRY"
            },
            {
              "symbol": "BAYZF"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-01T11:54:00+00:00",
    "headline": "Regeneron inks gene editing deal with startup Tessera",
    "summary": "The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a potential one-and-done treatment for alpha-1 antitrypsin deficiency.",
    "url": "https://www.biopharmadive.com/news/regeneron-gene-editing-deal-tessera-AATD/806650/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "54ff9385-61d2-3828-b5d5-5e74e1f9fc7c",
      "content": {
        "id": "54ff9385-61d2-3828-b5d5-5e74e1f9fc7c",
        "contentType": "STORY",
        "title": "Regeneron inks gene editing deal with startup Tessera",
        "description": "",
        "summary": "The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a potential one-and-done treatment for alpha-1 antitrypsin deficiency.",
        "pubDate": "2025-12-01T11:54:00Z",
        "displayTime": "2025-12-01T11:54:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "BioPharma Dive, an Industry Dive publication",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U3g5.ulK0vcCqcdyFlYvVw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DH6ljKWVk5FO27mUzvHUcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/regeneron-gene-editing-deal-tessera-AATD/806650/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-inks-gene-editing-deal-115400448.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]